Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O60906

UPID:
NSMA_HUMAN

ALTERNATIVE NAMES:
Lyso-platelet-activating factor-phospholipase C; Neutral sphingomyelinase

ALTERNATIVE UPACC:
O60906; Q5TED1; Q9BWR3

BACKGROUND:
The enzyme Sphingomyelin phosphodiesterase 2, with alternative names Neutral sphingomyelinase and Lyso-platelet-activating factor-phospholipase C, is pivotal in the hydrolysis of sphingomyelin, producing ceramide and phosphocholine. This enzyme's action on lyso-PC and sphingosylphosphocholine signifies its importance in cellular communication and apoptosis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Sphingomyelin phosphodiesterase 2 offers a promising avenue for the development of novel therapeutic approaches. By elucidating its role in cellular mechanisms, researchers can identify new targets for drug development, potentially leading to breakthrough treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.